Rebastinib
货号：
21465-25mg 基本售价：
9072.0 元 规格：
25 mg
产品信息
概述| 货号 | 21465-25mg |
| 描述 | Rebastinib is an orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM) as well as the gatekeeper mutant Abl1T315I(IC50 = 4 nM) and the activation loop mutant Abl1H396P.1 It also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar concentrations. Rebastinib inhibits mutant Abl1T315I signaling and prolongs survival in a mouse Ba/F3 cell allograft model.1,2 Rebastinib also exhibits in vivo antineoplastic activity against cells with the T674I point mutation of FIP1-like-1-platelet-derived growth factor receptor α.3 |
| 别名 | DCC-2036; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Chan, W.W.,Wise, S.C.,Kaufman, M.D., et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19(4), 556-568 (2011).
2.Eide, C.A.,Adrian, L.T.,Tyner, J.W., et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 71(9), 3189-3195 (2011).
3.Shen, Y.,Shi, X. and Pan, J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One 8(8), e73059 (2013).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 553.6 |
| 分子式 | C30H28FN7O3 |
| CAS号 | 1020172-07-9 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
